Mer receptor tyrosine kinase is a therapeutic target in pre–B-cell acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL) is currently treated with an intense regimen of chemotherapy yielding cure rates near 85%. However, alterations to treatment strategies using available drugs are unlikely to provide significant improvement in survival or decrease therapy-associated toxicities. Here...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Linger, Rachel M. A., Lee-Sherick, Alisa B., DeRyckere, Deborah, Cohen, Rebecca A., Jacobsen, Kristen M., McGranahan, Amy, Brandão, Luis N., Winges, Amanda, Sawczyn, Kelly K., Liang, Xiayuan, Keating, Amy K., Tan, Aik Choon, Earp, H. Shelton, Graham, Douglas K.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2013
Konular:
Lymphoid Neoplasia
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3757372/
https://ncbi.nlm.nih.gov/pubmed/23861246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-01-478156
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller